R3767-ONC-2431 PHASE II RANDOMIZED STUDY OF FIANLIMAB PLUS CEMIPLIMAB VERSUS CEMIPLIMAB PLUS PLACEBO IN FIRST-LINE TREATMENT OF PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) THAT IS POSITIVE FOR PD-L1 EXPRESSION
- Phase II
- Trial Category: Head and Neck
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields